1. Prediction and clinical utility of a contralateral breast cancer risk model.
- Author
-
Wendt C., Van Leeuwen F.E., Van Ongeval C., Van't Veer L.J., Wang Q., Westenend P.J., Schmidt M.K., Hooning M.J., Giardiello D., Steyerberg E.W., Hauptmann M., Adank M.A., Akdeniz D., Blomqvist C., Bojesen S.E., Bolla M.K., Brinkhuis M., Chang-Claude J., Czene K., Devilee P., Dunning A.M., Easton D.F., Eccles D.M., Fasching P.A., Figueroa J., Flyger H., Garcia-Closas M., Haeberle L., Haiman C.A., Hall P., Hamann U., Hopper J.L., Jager A., Jakubowska A., Jung A., Keeman R., Kramer I., Lambrechts D., Le Marchand L., Lindblom A., Lubinski J., Manoochehri M., Mariani L., Nevanlinna H., Oldenburg H.S.A., Pelders S., Pharoah P.D.P., Shah M., Siesling S., Smit V.T.H.B.M., Southey M.C., Tapper W.J., Tollenaar R.A.E.M., Van Den Broek A.J., Van Deurzen C.H.M., Wendt C., Van Leeuwen F.E., Van Ongeval C., Van't Veer L.J., Wang Q., Westenend P.J., Schmidt M.K., Hooning M.J., Giardiello D., Steyerberg E.W., Hauptmann M., Adank M.A., Akdeniz D., Blomqvist C., Bojesen S.E., Bolla M.K., Brinkhuis M., Chang-Claude J., Czene K., Devilee P., Dunning A.M., Easton D.F., Eccles D.M., Fasching P.A., Figueroa J., Flyger H., Garcia-Closas M., Haeberle L., Haiman C.A., Hall P., Hamann U., Hopper J.L., Jager A., Jakubowska A., Jung A., Keeman R., Kramer I., Lambrechts D., Le Marchand L., Lindblom A., Lubinski J., Manoochehri M., Mariani L., Nevanlinna H., Oldenburg H.S.A., Pelders S., Pharoah P.D.P., Shah M., Siesling S., Smit V.T.H.B.M., Southey M.C., Tapper W.J., Tollenaar R.A.E.M., Van Den Broek A.J., and Van Deurzen C.H.M.
- Abstract
Background: Breast cancer survivors are at risk for contralateral breast cancer (CBC), with the consequent burden of further treatment and potentially less favorable prognosis. We aimed to develop and validate a CBC risk prediction model and evaluate its applicability for clinical decision-making. Method(s): We included data of 132,756 invasive non-metastatic breast cancer patients from 20 studies with 4682 CBC events and a median follow-up of 8.8 years. We developed a multivariable Fine and Gray prediction model (PredictCBC-1A) including patient, primary tumor, and treatment characteristics and BRCA1/2 germline mutation status, accounting for the competing risks of death and distant metastasis. We also developed a model without BRCA1/2 mutation status (PredictCBC-1B) since this information was available for only 6% of patients and is routinely unavailable in the general breast cancer population. Prediction performance was evaluated using calibration and discrimination, calculated by a time-dependent area under the curve (AUC) at 5 and 10 years after diagnosis of primary breast cancer, and an internal-external cross-validation procedure. Decision curve analysis was performed to evaluate the net benefit of the model to quantify clinical utility. Result(s): In the multivariable model, BRCA1/2 germline mutation status, family history, and systemic adjuvant treatment showed the strongest associations with CBC risk. The AUC of PredictCBC-1A was 0.63 (95% prediction interval (PI) at 5 years, 0.52-0.74; at 10 years, 0.53-0.72). Calibration-in-the-large was-0.13 (95% PI:-1.62-1.37), and the calibration slope was 0.90 (95% PI: 0.73-1.08). The AUC of Predict-1B at 10 years was 0.59 (95% PI: 0.52-0.66); calibration was slightly lower. Decision curve analysis for preventive contralateral mastectomy showed potential clinical utility of PredictCBC-1A between thresholds of 4-10% 10-year CBC risk for BRCA1/2 mutation carriers and non-carriers. Conclusion(s): We developed a reasonab
- Published
- 2020